Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
RESEARCH TOOLSreports
Holding AU:PAR?
Track your performance easily
PAR Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.21 - AU$0.76
Previous CloseAU$0.25
Volume376.05K
Average Volume (3M)565.27K
Market Cap
AU$80.47M
Enterprise ValueAU$46.78M
Total Cash (Recent Filing)AU$39.67M
Total Debt (Recent Filing)AU$616.67K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Feb 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares OutstandingN/A
10 Day Avg. Volume776,154
30 Day Avg. Volume565,267
Standard Deviation0.20
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)6584.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Paradigm Biopharmaceuticals Ltd. News
PremiumCompany Announcements
Paradigm Biopharma Lists New Shares on ASX
PremiumCompany Announcements
Paradigm Biopharmaceuticals Embraces Corporate Governance
PremiumCompany Announcements
Paradigm Biopharma Reports Revenue Decline and Losses
PremiumCompany Announcements
Paradigm Biopharma Advances Clinical Trials with Fiscal Prudence
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks New ASX Quotation
PremiumCompany Announcements
Paradigm Biopharmaceuticals Advances Clinical Programs
PremiumCompany Announcements
Paradigm Biopharma Conducts Share Buy-back
PremiumCompany Announcements
Paradigm Submits Phase 3 OA Program to FDAOptions Prices
Currently, No data available
---
Ownership Overview
7.23% Insiders
0.27% Mutual Funds
0.08% Other Institutional Investors
92.42% Public Companies and
Individual Investors
PAR FAQ
What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest share price was AU$0.21 and its highest was AU$0.76 in the past 12 months.
What is Paradigm Biopharmaceuticals Ltd.’s market cap?
Currently, no data Available
When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2025 which is in 152 days.
How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
Paradigm Biopharmaceuticals Ltd. released its earnings results on Aug 23, 2024. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Paradigm Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Paradigm Biopharmaceuticals Ltd. pay dividends?
Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
Paradigm Biopharmaceuticals Ltd. has 350,364,350 shares outstanding.
What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Paradigm Biopharmaceuticals Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.174%.
Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:PAR
---
Paradigm Biopharmaceuticals Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PAR Sentiment 86%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.53%
12-Months-Change
Fundamentals
Return on Equity
-148.46%
Trailing 12-Months
Asset Growth
-59.03%
Trailing 12-Months
Company Description
Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company which engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic rhinitis.
---
Technical Analysis
CytoDyn
―
Inmune Bio
―
Northwest Biotherapeutics
―
Advaxis
―
Paradigm Biopharmaceuticals Ltd.
―
---